Idorsia 9M Revenue Flat; QUVIVIQ Sales Rise 54%
Swiss biopharma company Idorsia reported flat revenue for the first nine months of 2026, while QUVIVIQ sales increased 54%.
Related stories
三六零 Says Third-Quarter Revenue Fell 3.9% Year Over Year
M impact | EARNINGS | Oct 29, 2026, 09:38 AM UTC
三六零 Says Third-Quarter Net Profit Fell 32.1% Year Over Year
三六零 said its net profit fell 32.1% year over year in the third quarter.
M impact | EARNINGS | Oct 29, 2026, 09:38 AM UTC
Sheng Siong Group Reports Q3 Net Income of SGD44.6 Million
Sheng Siong Group posted Q3 net income of SGD44.6 million and gross margin of 32.2%.
M impact | EARNINGS | Oct 29, 2026, 09:37 AM UTC
Sheng Siong 9M FY26 Net Profit Rises 8% to S$125.5 Million
Sheng Siong reported 9M FY26 net profit of S$125.5 million, up 8% year-on-year.
M impact | EARNINGS | Oct 29, 2026, 09:36 AM UTC
Tecnotree raises 2026 revenue guidance
Tecnotree raised its revenue guidance for 2026.
M impact | EARNINGS | Oct 29, 2026, 09:35 AM UTC
Tecnotree Expects Mid- to High-Single-Digit Currency-Adjusted Revenue Growth in 2026
M impact | EARNINGS | Oct 29, 2026, 09:35 AM UTC